Interruption of apixaban doesn't impact bleeding in A-fib

December 21, 2017

(HealthDay)—For patients undergoing catheter ablation for nonvalvular atrial fibrillation (AF), both uninterrupted and minimally interrupted apixaban are associated with a very low rate of thromboembolic events, according to a study published online Dec. 20 in JACC: Clinical Electrophysiology.

Matthew R. Reynolds, M.D., from Lahey Hospital & Medical Center in Burlington, Mass., and colleagues randomized 300 patients undergoing for nonvalvular AF to uninterrupted or minimally interrupted peri-procedural apixaban. For comparison, a retrospective cohort of patients treated with uninterrupted warfarin at the same centers was matched to the apixaban-treated subjects.

The researchers identified no stroke/systemic embolism events. Overall, 11.3 percent of the 150 evaluable patients on uninterrupted apixaban and 9.7 percent of 145 evaluable patients on interrupted apixaban had clinically significant bleeding (risk difference, 1.7 percent; 95 percent confidence interval, −5.5 to 8.8 percent; P = NS). The rates of major bleeding were 1.3 and 2.1 percent in the uninterrupted apixaban and interrupted apixaban groups, respectively (risk difference, −0.7 percent; P = NS). For all apixaban combined, the rates of clinically significant and were similar (10.5 and 1.7 percent, respectively) to those of the matched warfarin group (9.8 and 1.4 percent, respectively).

"Both uninterrupted and minimally interrupted at the time of AF were associated with a very low rate of thromboembolic events, and rates of both major (<2 percent) and clinically significant bleeding, which were similar to uninterrupted warfarin," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Explore further: Apixaban lowers stroke risk in atrial fibrillation patients undergoing cardioversion

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Apixaban lowers stroke risk in atrial fibrillation patients undergoing cardioversion

August 28, 2017
Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented ...

Lower risk of gastrointestinal bleeding for apixaban

April 10, 2017
(HealthDay)—For patients receiving direct oral anticoagulant (DOAC) agents for non-valvular atrial fibrillation, apixaban is associated with a lower risk of gastrointestinal (GI) bleeding than rivaroxaban or dabigatran, ...

Apixaban Tx cost in A-fib meets U.S. norms for reasonable value

March 31, 2017
(HealthDay)—Apixaban therapy is cost-effective for atrial fibrillation from the perspective of the U.S. health care system, according to a study published online March 29 in JAMA Cardiology.

ISTH: Apixaban non-inferior to conventional treatment for VTE

July 1, 2013
(HealthDay)—For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according ...

Apixaban superior to warfarin for preventing stroke, reducing bleeding and saving lives

August 28, 2011
A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, apixaban results in ...

How safe and effective are new drugs for stroke prevention?

October 3, 2016
For decades, warfarin was the only oral blood thinner available to reduce the risk of stroke for patients with atrial fibrillation. Warfarin use is cumbersome, because it requires ongoing blood test to monitor the effect ...

Recommended for you

Novel genetic study sheds new light on risk of heart attack

October 12, 2018
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.

Researchers say ritual for orthodox Jewish men may offer heart benefits

October 11, 2018
A pilot study led by researchers at the University of Cincinnati (UC) College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

Seed oils are best for LDL cholesterol

October 9, 2018
If you want to lower your low-density lipoprotein cholesterol, called LDL or, colloquially, "bad cholesterol," the research is clear about one thing: You should exchange saturated fats with unsaturated fat. If you want to ...

Micropeptide restores heart function in mice

October 9, 2018
Researchers have discovered a micropeptide molecule that can restore normal heart function in mice, according to a study in eLife.

New risk test for sepsis for heart patients

October 5, 2018
Nearly one in four deaths in people with heart failure are caused by sepsis, according to new research.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.